Activin receptor type IIa variants and methods of use thereof
AssigneeKeros Therapeutics, Inc.
InventorsJasbir S. Seehra, Jennifer Lachey
Life of this patent
Estimating the term…
Abstract
The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.
Claims20
A method of increasing muscle mass in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a polypeptide comprising an extracellular activin receptor type IIa (ActRIIa) variant comprising a sequence of any one of SEQ ID NOs:
- 6-72 fused at its C-terminus to an Fc domain monomer, wherein the polypeptide is in the form of a dimer.
A method of treating a subject having a disease or condition involving muscle weakness or atrophy, comprising administering to the subject a therapeutically effective amount of a polypeptide comprising an extracellular ActRIIa variant comprising a sequence of any one of SEQ ID NOs:
- 6-72 fused at its C-terminus to an Fc domain monomer, wherein the polypeptide is in the form of a dimer.
A method of treating a subject having Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, amyotrophic lateral sclerosis, sarcopenia, cancer cachexia, or inclusion body myositis, comprising administering to the subject a therapeutically effective amount of a polypeptide comprising an extracellular ActRIIa variant comprising a sequence of any one of SEQ ID NOs:
- 6-72 fused at its C-terminus to an Fc domain monomer, wherein the polypeptide is in the form of a dimer.
Dependencies are inferred from the claim text.